Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

LPTX 11.26.2024

Full Press ReleaseSEC FilingsOur LPTX Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.06.2025 - Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 11.15.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.14.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors
  • 11.13.2024 - 8-K Current report

CAMBRIDGE, Mass.,Nov. 26, 2024/PRNewswire/ --Leap Therapeutics, Inc.(Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced thatDouglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36thAnnual Healthcare Conference inNew York, NY.

Leap Presentation Details:

Piper Sandler 36thAnnual Healthcare ConferenceDate:Wednesday, December 4, 2024Time:4:00 p.m. Eastern Time

A live webcast of the fireside chat may be accessed on the Investors page of the company's website athttps://investors.leaptx.com/, where a replay of the events will also be available for a limited time.

AboutLeap TherapeuticsLeap Therapeutics(Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information aboutLeap Therapeutics, visithttp://www.leaptx.comor view our public filings with theSECthat are available via EDGAR athttp://www.sec.govor viahttps://investors.leaptx.com/.

CONTACT:

Douglas E. OnsiPresident & Chief Executive OfficerLeap Therapeutics, Inc.617-714-0360donsi@leaptx.com

Matthew DeYoungInvestor RelationsArgot Partners212-600-1902leap@argotpartners.com

Leap Therapeutics logo (PRNewsfoto/LEAP Therapeutics)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-piper-sandler-36th-annual-healthcare-conference-302313181.html

SOURCELeap Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com